8th Sep 2025 01:18
(Alliance News) – AstraZeneca PLC said on Sunday that its Tagrisso lung cancer treatment plus chemotherapy delivered the longest survival benefits recorded in phase three trials.
The Cambridge, England-based pharmaceutical company said that Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years for patients with EGFR-mutated advanced lung cancer.
This compares with a median of approximately three years for Tagrisso monotherapy.
David Planchard, thoracic oncologist at Gustave Roussy Institute of Oncology and principal investigator for the trial, said: “The fundamental goals of lung cancer treatment are to extend survival while preserving patients' quality of life. These compelling results, which demonstrated unprecedented median overall survival, show this combination can achieve both of these goals and support osimertinib, with or without the addition of chemotherapy, as the standard of care for patients with 1st-line advanced EGFR-mutated lung cancer.”
AstraZeneca shares closed 0.5% lower at 12,124.00 pence in London on Friday.
By Lachlan Colquhoun, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca